Biosynthesis and Characterization of Vosoritide by <i>Escherichia coli</i>
Vosoritide is a therapeutic peptide that promotes skeletal growth by targeting the NPR-B receptor and was approved in 2021 for the treatment of achondroplasia. However, its high production cost poses a considerable economic burden on patients, limiting its widespread use. This study aims to establis...
Saved in:
| Main Authors: | Shuaiyi Huang, Xiaoyue Hu, Tao Luo, Jun Xu, Yu Duan, Jianguang Lu, Jun Feng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Georg Thieme Verlag KG
|
| Series: | Pharmaceutical Fronts |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/a-2647-7793 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Integrating vosoritide therapy with limb surgery in paediatric patients with achondroplasia: real-life experiences
by: Anna Elsa Maria Allegri, et al.
Published: (2025-07-01) -
Current Strategies and Future Prospects of Achondroplasia Treatment : A Systemic Review
by: Daria Bednarczyk, et al.
Published: (2025-03-01) -
Hypertrichosis associated with the use of C-type natriuretic peptide analogue: a case report
by: Juan Llerena Clinton, et al.
Published: (2025-04-01) -
Advances in the treatment of achondroplasia
by: Patrycja Jędrzejewska-Rzezak
Published: (2025-04-01) -
Management of sleep-disordered breathing in achondroplasia: guiding principles of the European Achondroplasia Forum
by: Brigitte Fauroux, et al.
Published: (2025-05-01)